Formosa Pharmaceuticals is a preclinical and clinical stage biopharmaceutical company with focus in the therapeutic areas of ophthalmology, oncology, and anti-infectives.
News Highlight
- Advancing Women’s Football Professionalization! Formosa Pharmaceuticals Supports Taipei Bravo’s Japan Exchange to Deepen International ESG Commitments
- See the Power in the Small: Formosa Pharmaceuticals Supports Taipei Bravo Women’s Football in Spirited 2026 WBC Cheer Campaign, Fulfilling ESG Health Commitments
- Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Formosa Pharma is developing a unique pipeline consisting of risk-diverse development modes, including 505(b)(2), biosimilars, and NCEs. Our proprietary APNT™ nanoparticle formulation platform, from which lead program APP13007 is derived, is available for application to drug candidates in need of improving pharmacokinetics and bioavailability.
